In-use periods, and the ones nobody can give you
The air shot before a pen injection removes air from the cartridge and confirms flow. Skipping it can mean a materially reduced dose, and it is skipped constantly.
Dosing
Label schedules, clinical practice, dose holding, and the pharmacokinetics that constrain both.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Maximum tolerated is not maximum approved
Weight reduction in the long programmes flattens at roughly sixty to seventy-two weeks. The timing is consistent, predictable and almost never mentioned in advance.
What a month without the drug does to tolerability
Concentrations fall by half a week, so a month away leaves a small fraction of steady state. Resuming at the previous dose presents the receptor with a step it has not seen…
The ceiling is a tolerability finding, not an efficacy one
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
What the anaesthetists said, and then said again
This is the single interaction with ordinary medical care that patients most need to disclose, and it is the one most often not asked about.
The restart nobody plans for
The convention — resume lower, re-escalate — is not caution. It follows directly from the elimination half-life.
The trade has decided the ceiling is arbitrary. The trials disagree.
Where the curve flattens, what flattens with it, and what does not.
Spain pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Four millimetres is enough, and the data says so
Longer needles reach muscle in lean limbs, and intramuscular delivery of a long-acting depot changes absorption in ways nobody wants.
Seven days, four weeks, one number: how liraglutide exposure actually accumulates
Half-life, accumulation ratio and time to steady state are three separate quantities, and confusing them produces most of the bad advice in circulation.
The withdrawal trials, read as designs rather than warnings
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Background rates, and why they matter for attribution
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
The eighteenth month, and the conversation that should have happened in the third
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
Poland pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
Do you need the top of the ladder?
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
What the new South Korea guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The shortage years, and what they taught about interruption
The trials studied planned withdrawal. Almost nobody stops that way.
Canada pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.